In several large series that were published before 1959, the 2 yr mortality of patients with untreated malignant hypertension approached 90%. Since the evaluation of a majority of those patients, there have been a number of pharmacologic and technical advances made in the management of both benign and malignant hypertension and the management of renal failure. No recent reports of morbidity and mortality in large series of patients treated for malignant hypertension have been able to keep pace with the rapid advances in all phases of the management of this life threatening syndrome. However, it has been suggested that the frequency of development of the malignant hypertension phase has been reduced, possibly as the result of more efficient recognition and treatment of the benign phases of the disease. Control in the early stages of the malignant phase of hypertension has been more successful with the introduction of potent diuretics and potent antihypertensive agents. Technical advances in dialysis and the increased availability of dialysis, as well as improved understanding of complications in long term repetitive dialysis patients, have added new and successful dimensions to the management of uremia. In addition, achievements in the field of renal transplantation now offer the uremic patient freedom from the confines of artificial means of life support. While the malignant phase of hypertension is still a threatening disease today, its mortality has been reduced in the past 2 decades by the application of modern modes of therapy.
|Original language||English (US)|
|Number of pages||11|
|Journal||Archives of internal medicine|
|State||Published - May 1974|
ASJC Scopus subject areas
- Internal Medicine